Navigation Links
Stem Cell Transplant May Help Aggressive MS: Study

By Amanda Gardner
HealthDay Reporter

MONDAY, March 21 (HealthDay News) -- Stem cell transplants may hold some hope for patients with rapidly progressing multiple sclerosis, the authors of a long-term study report.

The controversial treatment, known as hematopoietic stem cell transplantation (HSCT), involves ablating, or removing, the patients' immune and other blood cells, then replacing it with new bone marrow stem cells from the same patient.

The idea is to "reset the thermostat and start fresh," said Dr. Aaron Miller, chief medical officer for the National Multiple Sclerosis Society and a professor of neurology at Mount Sinai School of Medicine in New York City.

But Miller, who was not involved in the study, doubts the procedure will become a viable option for patients with aggressive multiple sclerosis.

"This is a very heroic form of therapy for multiple sclerosis [MS], which is unlikely, in my view, ever to have a major impact on the field," added Miller. "It's a substantially risky therapy -- the mortality rates have been in the 2-3 percent range . . . and it's hugely expensive."

MS is a disease of the nervous system. There is no known cause or cure, and in severe cases patients may be unable to write, speak or walk.

This study, published in the March 22 issue of Neurology, was begun 15 years ago. Back then, "perhaps we didn't have other good alternatives for aggressive disease," he said. "I think we now have better and safer alternatives."

Those alternatives include the biologic therapies Tysabri (natalizumab) and Gilenya (fingolimod), approved in 2006 and 2010, respectively. But Miller emphasized these can only be considered "potentially" more effective than HSCT because the two have never been tested head-to-head.

The trial organizers reported earlier that 80 percent of patients receiving HSCT treatment had stabilized disease after five years. They also noted positive brain changes on an MRI.

Now, after 15 years, the authors report that overall 25 percent of the 35 initial patients are stabilized. The success rate was better -- 44 percent -- for those with active brain lesions, signaling aggressive disease, they found.

Many had a lessening of their disability, and fewer and smaller lesions in the brain.

But two participants, or 6 percent, died of complications from the transplant.

Research on this aggressive therapy is continuing, say the authors, from Aristotle University of Thessaloniki Medical School in Greece.

But more information might be hard to come by because the treatment's high mortality rate makes it difficult to recruit patients.

Still, they said, HSCT might be a "salvage" therapy for hard-to-treat MS.

"It's a possible treatment strategy, but it remains to be seen how much of a treatment option it is," said Dr. Mark Keegan, associate professor of neurology at the Mayo Clinic in Rochester, Minn.

"We do need ways to treat people with aggressive MS," he added.

More information

Visit the National Multiple Sclerosis Society for more on this disease.

SOURCES: Aaron Miller, M.D., chief medical officer, National Multiple Sclerosis Society, and associate professor of neurology and director, Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Mount Sinai School of Medicine, New York City; Mark Keegan, M.D., associate professor of neurology, Mayo Clinic, Rochester, Minn.; March 22, 2011 Neurology

Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Survival matching should be used to allocate donated kidneys to transplant recipients
2. Transplant Drug May Fight Rare Lung Disorder
3. Alcohol abuse history influences quality of life following liver transplant
4. Transplanting umbilical cord and menstrual blood-derived stem cells offer hope for disorders
5. White Patients Most Likely to Get Kidney Transplants: Study
6. Kidney Transplant Patients Urged to Keep Fit to Survive
7. Study Rates Success of Corneal Transplants in Kids
8. Redesign of US donor-liver network could boost transplants by several hundred per year
9. Researchers work at the frontiers of islet cell transplantation
10. Gene protects lung from damage due to pneumonia, sepsis, trauma, transplants
11. Transplanted human placenta-derived stem cells show therapeutic potential in stroke models
Post Your Comments:
Related Image:
Stem Cell Transplant May Help  Aggressive MS: Study 
(Date:12/1/2015)... ... December 01, 2015 , ... Baptist Medical Center Jacksonville ... is the only hospital in the region providing what is known as the ... pacing patients were revealed recently at a medical conference and published in The ...
(Date:12/1/2015)... ... December 01, 2015 , ... December 1, 2015 ... of the company’s growing product line of food safety and seafood fraud prevention ... (Oncorhynchus nerka) – allow InstantLabs to offer fast, reliable species identification for the ...
(Date:12/1/2015)... ... December 01, 2015 , ... Diabetic foot wounds ... Podiatrists are well aware that psychology-based patient non-compliance (disobedience of a health care ... to diseases of the diabetic foot. The American Board of Multiple Specialties ...
(Date:12/1/2015)... ... 01, 2015 , ... SAN FRANCISCO, Calif. (December 1, 2015) ... has awarded Education and Developmental Therapies (EDT), an Applied Behavior Analysis (ABA) service ... special needs providers that excel in synthesizing the areas of clinical quality, staff ...
(Date:12/1/2015)... ... December 01, 2015 , ... PYA’s latest white paper, “ ... a main “pain point” for merging or aligning healthcare provider organizations—when mergers and ... signed. This quick-read guidance suggests that failing to recognize the power of ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... 2015 ... of the "2016 Europe Enteric ... Coli, Enterovirus, Rhinovirus, Rotavirus, Salmonella, Shigella, ... offering. --> ) ... "2016 Europe Enteric Disease Testing ...
(Date:12/1/2015)... , Dec. 1, 2015 CytRx Corporation (NASDAQ: ... specializing in oncology, today announced that it has reached ... pivotal global Phase 3 clinical trial of aldoxorubicin in ... originally estimated to be completed in Q1 2016. The Phase ... under a Special Protocol Assessment from the FDA at ...
(Date:12/1/2015)... Dec. 1, 2015   Craneware, Inc ., ... solutions, today announced the company will showcase a ... ® solution at the American Society ... Meeting . The new features are focused on ... monitoring and managing enterprise-wide pharmacy charges to ensure ...
Breaking Medicine Technology: